Flerie AB (publ) (FLERIE.ST) has a MoatMap StockRank of 25/100 based on Quality (42/100), Value (43/100), and Momentum (27/100) factor scores. The current signal is SELL. An active healthcare investor/holding company that does not meet our criteria for direct, high-conviction exposure to quality compounders with predictable owner earnings.
Flerie AB is an active Swedish life science investment company focused on backing pioneering biotechnology, drug development, and pharmaceutical service companies globally. Founded by industry veterans, the firm provides long-term capital and strategic guidance to help portfolio companies navigate clinical trials and commercialization. Flerie's unique competitive advantage lies in its deep sector expertise and its specialized focus on the high-margin contract development and manufacturing (CDMO) space.
| Price | $2.34 |
| Market Cap | $242M |
| P/E (Forward) | -53.66 |
| Price/Book | 0.57 |
| Return on Equity | -14.9% |
| Return on Invested Capital | -22.4% |
| Debt/Equity | 0.05 |
| Gross Margin | 0.0% |
| Operating Margin | -11800.0% |
| Revenue Growth | -87.5% |
| Free Cash Flow | $132K |
Flerie AB (publ) operates in the Biotechnology industry, part of the Healthcare sector (Sweden).